New hope for Hard-to-Treat breast cancer: targeted combo trial launches
Disease control
Recruiting now
This study tests whether adding a new drug (JS105) to two standard medications (dalpiciclib and fulvestrant) can help people with a certain genetic form of advanced breast cancer live longer without their disease getting worse. About 312 adults with PIK3CA-mutated, HR-positive, H…
Phase: PHASE3 • Sponsor: Risen (Suzhou) Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 01, 2026 16:00 UTC